Cancer Battle: The closure of a Federal Court case instigated by MSD in 2014 is just one result of a global settlement ending litigation between it and BMS over alleged infringement of patents on Opdivo.
New Minister: Australia's medicines industry yesterday clambered to welcome newly appointed minister Greg Hunt to the health portfolio, with numerous advocacy groups indicating they would soon be knocking on his door.
Pipeline: The company's global CEO, Ken Frazier, says Keytruda's market position has been strengthened by the FDA extending a rapid review to it latest filing for a first time combination with chemo in NSCLC.
Bayer registers five year contraceptive
Bayer has won TGA approval for an intrauterine contraceptive indicated for contraception up to five years while Aspen Pharma's status as the only PBS supplier of ADHD treatment dexamphetamine looks like it's under threat.
How much damage could Trump do to pharma?
With only a couple of days to go until Donald Trump is inaugurated as the 45th President of the United States, his tendency to bash pharma has many worried. Could he damage the US industry enough to affect Australia?